Onyx seeks expedited FDA review of myeloma drug carfilzomib

09/28/2011 | Xconomy

Onyx Pharmaceuticals has asked the FDA for priority evaluation of carfilzomib, a treatment candidate for multiple myeloma. Clinical data show that the drug reduces tumor size in patients who have received at least two previous therapies.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC